Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-1822PMID 19188187PMCID PMC3722558
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of Heterozygosity at the BRCA 2 Locus Detected byMultiplex Ligation-Dependent ProbeAmplification is Common in Prostate Cancers fromMenwith a Germline BRCA 2 Mutation

  2008cited by this paper
• Loss of Heterozygosity at the BRCA2 Locus Detected by Multiplex Ligation-Dependent Probe Amplification is Common in Prostate Cancers from Men with a Germline BRCA2 Mutation

  2008cited by this paper
• Cumulative association of five genetic variants with prostate cancer.

  2008cited by this paper
• Germline Mutations in the BRCA2 Gene and Susceptibility to Hereditary Prostate Cancer

  2007cited by this paper
• Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes

  2007cited by this paper
• Multiple regions within 8q24 independently affect risk for prostate cancer

  2007cited by this paper
• Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer

  2007cited by this paper
• Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

  2007cited by this paper
• Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24

  2007cited by this paper
• Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

  2006cited by this paper
• Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men

  2006cited by this paper
• A common variant associated with prostate cancer in European and African populations

  2006cited by this paper
• Cancer risks in BRCA2 families: estimates for sites other than breast and ovary

  2005cited by this paper
• Re: BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.

  2004cited by this paper
• BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews

  2004cited by this paper
• BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.

  2004cited by this paper
• Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing.

  2004cited by this paper
• Where are the prostate cancer genes?—A summary of eight genome wide searches

  2003cited by this paper
• Relative risk of prostate cancer for men with affected relatives: Systematic review and meta‐analysis

  2003influential reference
• Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma

  2003cited by this paper
• Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status

  2003cited by this paper
• Genotype-phenotype analysis of the Crohn’s disease susceptibility haplotype on chromosome 5q31

  2003cited by this paper
• Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.

  2003cited by this paper
• The effect of a single BRCA2 mutation on cancer in Iceland

  2002cited by this paper
• Cancer Incidence in BRCA1 mutation carriers.

  2002cited by this paper
• Risk of cancer in BRCA1 and BRCA2 mutation-positive and -negative breast cancer families (Finland)

  2001cited by this paper
• BRCA1 and BRCA2 have a limited role in familial prostate cancer.

  2000cited by this paper
• Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.

  2000cited by this paper
• The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.

  2000cited by this paper
• The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.

  1999cited by this paper
• No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer

  1999cited by this paper
• Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium

  1999cited by this paper
• Cancer risks in BRCA2 mutation carriers.

  1999cited by this paper
• Incidence of malignant tumours in relatives of BRCA1 and BRCA2 germline mutation carriers.

  1999cited by this paper
• Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men

  1999cited by this paper
• THE PREVALENCE OF THE MAJOR "JEWISH MUTATIONS" BRCA1 AND BRCA2 IN PROSTATE CANCER PATIENTS IN ISRAEL

  1999cited by this paper
• Applied Regression Analysis and Multivariable Methods

  1999cited by this paper
• Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients.

  1998cited by this paper
• BRCA2 mutation in Icelandic prostate cancer patients

  1997cited by this paper
• The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

  1997cited by this paper
• Elimination of false-positive signals in enhanced chemiluminescence (ECL) detection of amplified HPV DNA from clinical samples.

  1995cited by this paper
• Identification of the von Hippel-Lindau disease tumor suppressor gene.

  1993cited by this paper
• APC mutations occur early during colorectal tumorigenesis

  1992cited by this paper
• Risk assessment for case-control subgroups by polychotomous logistic regression.

  1986cited by this paper
• International Agency for Research on Cancer.

  1985cited by this paper
• Statistical methods in cancer research: volume 1- The analysis of case-control studies

  1980cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

  2026cites this paper
• Germline BRCA2 Mutation and Lynch Syndrome in a Patient With Multiple Primary Malignancies

  2025cites this paper
• Clinical Significance of Germline Variants in the BRCA2 Gene and Their Association With Prostate Cancer Risk in Polish Men: A Case-Control Study

  2025cites this paper
• Chest Pain as a Symptom of Early-Onset Metastatic Prostate Cancer: Exploring the Role of Screening

  2025cites this paper
• Genetic determinants of prostate cancer predisposition in Ashkenazi Jews.

  2025influential citation
• Integrating molecular diagnostics for early prostate cancer detection

  2025cites this paper
• DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic Prostate Cancer

  2023cites this paper
• Whole exome germline sequencing in early‐onset prostate cancer patients: Genomic findings and clinical outcomes

  2023cites this paper
• Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications.

  2023cites this paper
• Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors.

  2023cites this paper
• Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis

  2023influential citation
• Prostate Cancer: Advances in Genetic Testing and Clinical Implications

  2023cites this paper
• Racial Differences in Germline Genetic Testing for Prostate Cancer: A Systematic Review

  2023cites this paper
• Prevalence of Germline BRCA1/2 Variants in Ashkenazi and Non-Ashkenazi Prostate Cancer Populations: A Systematic Review and Meta-Analysis

  2023cites this paper
• Prostate Cancer: Germline Mutations in BRCA1 and BRCA2

  2023cites this paper
• Medicaid Expansions: Probing Medicaid’s Filling of the Cancer Genetic Testing and Screening Space

  2022cites this paper
• Racial Differences in Prostate Cancer Characteristics and Cancer-Specific Mortality: An Overview

  2022cites this paper
• Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

  2022cites this paper
• BRCA associated prostate cancer. BRCA heredity of one family

  2022cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection Version 1 . 2022 —

  2022cites this paper
• Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients

  2022cites this paper
• Genetic medicine is accelerating in Japan

  2022cites this paper
• Discriminatory Gleason grade group signatures of prostate cancer: An application of machine learning methods

  2022cites this paper
• Prostate‐specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer‐specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer

  2021cites this paper
• Cancer genetic testing in marginalized groups during an era of evolving healthcare reform

  2021cites this paper
• Current evidences of BRCA mutations in genitourinary and gynecologic tumors: a scoping review

  2021cites this paper
• BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis

  2021influential citation
• Differences in Ovarian and Other Cancers Risks by Population and BRCA Mutation Location

  2021cites this paper
• Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history

  2021cites this paper
• Philadelphia Prostate Cancer Genetic Consensus Conference 2019 and implications for military medicine.

  2021cites this paper
• Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome

  2021cites this paper
• BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored

  2021cites this paper
• Cancer genetic testing in marginalized groups during an era of evolving healthcare reform.

  2021cites this paper
• Germline Genetics of Prostate Cancer: Prevalence of Risk Variants and Clinical Implications for Disease Management

  2021cites this paper
• Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention

  2021cites this paper
• Genetic predisposition to prostate cancer: an update

  2021cites this paper
• Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021cites this paper
• Comprehensive evaluation of BRCA1/2 variant interpretation ability among laboratories in China

  2021cites this paper
• Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study☆

  2020cites this paper
• Immunohistochemical expression of BRCA1 and BRCA2 in a cohort of Ugandan men with prostate cancer: an analytical cross-sectional study

  2020cites this paper
• Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.

  2020cites this paper
• Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021

  2020cites this paper
• Intricate Interplay of Entwined Metabolic and Inflammatory Life-threatening Processes in Tumor Lysis Syndrome Complicating Prostate Cancer: A Systematic Review with a Single Institution Experience

  2020cites this paper
• Cancer Genetics and Therapeutic Opportunities in Urologic Practice

  2020cites this paper
• BRCA1 Is a Novel Prognostic Indicator and Associates with Immune Cell Infiltration in Hepatocellular Carcinoma

  2020cites this paper
• BRCA2 gene mutation and prostate cancer risk

  2020cites this paper
• Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

  2020cites this paper
• A REVIEW ON THE MUTATIONS OF THE BRCA 1 GENE ON NEUROCOGNITIVE DISORDERS

  2020influential citation
• A first Japanese case of neuroendocrine prostate cancer accompanied by lung and brain metastasis with somatic and germline BRCA2 mutation

  2019cites this paper
• Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

  2019cites this paper
• Redefining the Bladder Cancer Phenotype using Patterns of Familial Risk

  2019cites this paper
• Le carcinome intracanalaire de la prostate : indication potentielle pour la radiothérapie adjuvante

  2019cites this paper
• A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer

  2019cites this paper
• Germline genetics in localized prostate cancer.

  2019cites this paper
• The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.

  2019cites this paper
• Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

  2019cites this paper
• Cancer Health Disparities

  2019cites this paper
• The Prostate

  2019cites this paper
• Hereditary Cancer Syndromes: Risk Assessment and Genetic Counseling

  2019cites this paper
• Carcinogenicity assessment: Addressing the challenges of cancer and chemicals in the environment

  2019cites this paper
• Germline mutations in PPFIBP2 are associated with lethal prostate cancer

  2018cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities

  2018cites this paper
• Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer

  2018cites this paper
• Population masculine au sein des familles avec mutation germinale dans les gènes BRCA1 et BRCA2 aspects cliniques et pathologiques des cancers

  2018influential citation
• Screening for prostate cancer.

  2017cites this paper
• Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis

  2017cites this paper
• Case report: human papilloma virus type 120-related papillomatosis mimicking laryngeal carcinoma

  2017cites this paper
• Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation.

  2017cites this paper
• Rezidiv-Analyse von Prostatakarzinom-Patienten : diagnostische und prognostische Bedeutung des Prostate Health Index

  2017cites this paper
• Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

  2017cites this paper
• Update on Screening for Urological Malignancies

  2017cites this paper
• The Role of Metastasis Suppressor CD82 in the Deactivation of the c-Met Signaling Pathway in Prostate Cancer

  2017cites this paper
• Germline BRCA mutation in male carriers—ripe for precision oncology?

  2017cites this paper
• on genetic testing in carcinoma of the prostate gland : An update

  2017cites this paper
• Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.

  2017cites this paper
• Familial prostate cancer.

  2016cites this paper
• Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer

  2016cites this paper
• Management of the Patient with a Genetic Predisposition for Breast Cancer

  2016cites this paper
• Prolactin inhibits a major tumor-suppressive function of wild type BRCA1.

  2016cites this paper
• Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer

  2016cites this paper
• Polymorphism rs144848 in BRCA2 may Reduce Lung Cancer Risk in Women: A Case-Control Study in Southeast China

  2016cites this paper
• How I Do It: Genetic counseling and genetic testing for inherited prostate cancer.

  2016cites this paper
• Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21

  2016cites this paper
• Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis.

  2016cites this paper
• NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016.

  2016cites this paper
• NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines ® ) Prostate Cancer Early Detection

  2016cites this paper
• Cascade profiling of the ubiquitin-proteasome system in cancer

  2015cites this paper
• The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers

  2015influential citation
• Genetic predisposition to prostate cancer: Update and future perspectives.

  2015cites this paper
• NCCN Guidelines Version 2 . 2017 Table of Contents Prostate Cancer Early Detection

  2015cites this paper
• An Application of Multinomial Logistic Regression to Assess the Factors Affecting the Women to Be Underweight and Overweight: A Practical Approach. -

  2015cites this paper
• Computer-Aided Detection and diagnosis for prostate cancer based on mono and multi-parametric MRI: A review

  2015cites this paper
• Characteristics of screen-failures in prostate cancer screening

  2015cites this paper
• Nuevas estrategias terapéuticas para el cáncer de próstata

  2015cites this paper
• Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2

  2015cites this paper
• Prioritization of potential candidate disease genes by topological similarity of protein-protein interaction network and phenotype data

  2015cites this paper
• Familial clustering of breast and prostate cancer and risk of postmenopausal breast cancer in the Women's Health Initiative Study

  2015cites this paper
• Prostate Cancer Early Detection, Version 2.2015

  2015cites this paper